Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.
Am J Cardiol. 2010 Jun 1;105(11):1528-34. doi: 10.1016/j.amjcard.2010.01.005. Epub 2010 Apr 14.
In patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (pPCI), early reperfusion is believed to improve left ventricular systolic function and reduce mortality; however, long-term (>1 year) data are sparse. In the DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) study, 686 patients with ST-segment elevation myocardial infarction were treated with pPCI. Long-term mortality was obtained during 3 years of follow-up. We classified the patients according to the symptom-to-balloon time (<3, 3 to 5, and > or =5 hours). The groups were compared using a Cox proportional hazards regression model adjusted for confounding factors. The left ventricular systolic ejection fraction was estimated by echocardiography before discharge. Coronary flow was evaluated using the Thrombolysis In Myocardial Infarction score. Mortality did not differ between the 2 earliest symptom-to-balloon groups, and they were therefore combined into 1 group in the analysis of survival. Mortality was significantly increased for patients with a symptom-to-balloon time > or =5 hours (hazard ratio 2.36, 95% confidence interval 1.51 to 3.67, p <0.001), a difference that remained significant after controlling for confounding factors (adjusted hazard ratio 2.44, 95% confidence interval 1.31 to 4.54, p = 0.007). The symptom-to-balloon time was inversely associated with a left ventricular systolic ejection fraction of < or =40% (19.7% vs 22.8% vs 33.1%, p = 0.036), with the latter a major predictor of 3-year mortality in this cohort (hazard ratio 6.02, 95% confidence interval 3.68 to 9.85, p <0.001). A shorter symptom-to-balloon time was associated with greater rates of Thrombolysis In Myocardial Infarction 3 flow after pPCI (86.5% vs 80.9% vs 75.7%, p = 0.002). In conclusion, a shorter symptom-to-balloon time was associated with improved coronary flow, an increased likelihood of subsequent left ventricular systolic ejection fraction >40%, and greater 3-year survival in patients with ST-segment elevation myocardial infarction treated with pPCI.
在接受直接经皮冠状动脉介入治疗 (pPCI) 的 ST 段抬高型心肌梗死患者中,早期再灌注被认为可以改善左心室收缩功能并降低死亡率;然而,长期(>1 年)数据较为缺乏。在 DANish Trial in Acute Myocardial Infarction-2(DANAMI-2)研究中,686 例 ST 段抬高型心肌梗死患者接受了 pPCI 治疗。在 3 年的随访期间获得了长期死亡率数据。我们根据症状至球囊时间(<3、3 至 5 和 >=5 小时)对患者进行分类。使用 Cox 比例风险回归模型调整混杂因素后比较各组。在出院前通过超声心动图估计左心室收缩射血分数。使用心肌梗死溶栓治疗(TIMI)评分评估冠状动脉血流。症状至球囊时间>=5 小时的患者死亡率显著升高(危险比 2.36,95%置信区间 1.51 至 3.67,p <0.001),在控制混杂因素后差异仍然显著(调整危险比 2.44,95%置信区间 1.31 至 4.54,p = 0.007)。症状至球囊时间与左心室收缩射血分数 <=40%呈负相关(19.7%比 22.8%比 33.1%,p = 0.036),后者是该队列 3 年死亡率的主要预测因素(危险比 6.02,95%置信区间 3.68 至 9.85,p <0.001)。较短的症状至球囊时间与 pPCI 后 TIMI 血流 3 级的更高发生率相关(86.5%比 80.9%比 75.7%,p = 0.002)。总之,在接受 pPCI 治疗的 ST 段抬高型心肌梗死患者中,较短的症状至球囊时间与改善的冠状动脉血流、随后左心室收缩射血分数 >40%的可能性增加以及 3 年生存率的提高相关。